Coherus BioSciences, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CHRS, updated each market day.
CHRS AI Sentiment
AI predicts Coherus BioSciences, Inc. stock is likely to increase over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Coherus BioSciences, Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Sector
Exchange
Market Cap
$190,036,188
Cap Tier
Employees
144
Headquarters
REDWOOD CITY, CA
Listed Since
Nov. 6, 2014
Website
CHRS Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CHRS Volatility
Coherus BioSciences, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
